H&T Presspart said this week that it acquired the global rights to Hovione Technology‘s capsule-based dry powder inhaler. The company launched a next-gen version of the inhaler called PowdAir Plus at this year’s Respiratory Drug Delivery Europe.
The PowdAir Plus device is made of plastic and its 4-component design lessens manufacturing, assembly and production costs, according to H&T Presspart.
The device opens the pharmaceutical capsule once the tray is loaded and closed, eliminating the need for patients to actively pierce the capsule, the company said.
“This is a strategically significant partnership for H&T Presspart and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for respiratory patients,” chairman Peter Schmelzer said in prepared remarks. “This partnership supports our strategy to respond to the rapidly growing demand for dry powder inhalers across a range of needs, with this collaboration focused on providing a solution for developing markets.”
“We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialization and global distribution, we are very confident about success,” Hovione CEO Peter Villax added.
